At ALL, innovation is at the heart of how we discover, develop, and bring new medicines to patients. We are committed to creating the right environment, resources, and infrastructure to support bold thinking, while fostering a culture that encourages curiosity, collaboration, and continuous learning. We bring together talented people and actively look beyond our own organisation to access new ideas, expertise, and capabilities.Our ambition is to create a home for innovation — an inspiring environment where creative thinkers can challenge conventions, explore new possibilities, and turn ambitious ideas into meaningful advances. As an R&D-driven organisation, we are focused on what comes next: transforming today’s scientific opportunities into the solutions of tomorrow.
We operate leading-edge facilities spanning discovery, research, development, and manufacturing, with more than 25% of our revenue continually reinvested into R&D. This strong commitment to research positions us among Europe’s most R&D-focused and agile biopharmaceutical organisations. Our modern, high-quality infrastructure includes two strategic research centres, two manufacturing facilities, and three development sites currently being established. Together, these locations form a global R&D network across three countries, enabling us to combine scientific expertise, advanced capabilities, and efficient collaboration across regions.
Our advanced laboratories bring together highly skilled specialists who design, optimise, and scale API processes to meet the rigorous requirements of our manufacturing operations. We focus on developing flexible, customer-specific solutions, including precise control of Particle Size Distribution through advanced micronization technologies.By combining technical expertise with a strong understanding of regulatory expectations, we tailor our API development approach to support the individual needs of each customer throughout the development, scale-up, and commercialisation of their finished dosage form (FDF) products
